RAS mutational testing, which should include KRAS and NRAS codons 12 and 13 of exon 2, 59 and 61 of exon 3, and 117 and 146 of exon 4 ("expanded" or "extended" RAS), must be performed in patients who are being considered for anti-EGFR receptor therapy. Clinical trial data have shown that patients with CRC carrying activating mutations of KRAS affecting exon 2 codons 12 and 13 did not benefit from anti-EGFR monoclonal antibody therapy.
Learn more about KRAS mutations in CRC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ali Alqahtani. Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer - Medscape - Jun 17, 2022.
Comments